Please ensure Javascript is enabled for purposes of website accessibility

Why Editas Medicine Stock Is Bouncing Back Today

By Keith Speights - Updated Mar 9, 2021 at 11:53AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A strong overall stock market performance is lifting the biotech stock.

What happened

It's been a tough year for Editas Medicine (EDIT -7.83%) so far. As of the market close on Monday, the stock was down 42%. But shares of Editas were rebounding by 8.2% as of 11:25 a.m. EST on Tuesday. The biotech didn't report any news. Instead, Editas' share price was buoyed by the overall stock market resurgence.

So what

Should investors read a lot into today's gain? Probably not. 

The stock market is enjoying a good day in large part because of anticipation that the $1.9 trillion stimulus bill that's being voted on in the U.S. House of Representatives today will help boost the economy. And the legislation probably will spur economic activity.

DNA with a portion separated

Image source: Getty Images.

However, clinical-stage biotech stocks such as Editas aren't impacted all that much by what goes on with the economy. Clinical studies and progress toward regulatory approval are much more important for companies like Editas.

On the other hand, part of the reason behind Editas' steep decline, especially in recent weeks, has been due to investors souring on growth stocks. If today's gains instill renewed confidence among investors, it could work to Editas' benefit.

Now what

The most important thing for investors to watch with Editas Medicine going forward is its pipeline progress. The company expects to report initial results from its early-stage study evaluating EDIT-101 in treating rare genetic eye disease Leber congenital amaurosis 10 later this year. Editas plans to kick off a phase 1/2 study of EDIT-301 in treating sickle cell disease in 2021 as well.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Editas Medicine, Inc. Stock Quote
Editas Medicine, Inc.
$10.72 (-7.83%) $0.91

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.